Page last updated: 2024-12-05

loviride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3963
CHEMBL ID37624
SCHEMBL ID247781
MeSH IDM0214090

Synonyms (37)

Synonym
bdbm50030539
2-(2-acetyl-5-methyl-phenylamino)-2-(2,6-dichloro-phenyl)-acetamide
r 89439
r89439
(+/-)-2,6-dichloro-.alpha.-[(2-acetyl-5-methylphenyl)amino]benzamide
147362-57-0
.alpha.-apa
2-(2-acetyl-5-methyl-anilino)-2-(2,6-dichlorophenyl)acetamide
loveride
loviride
D04786
loviride (usan/inn)
r-89439
benzeneacetamide, alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-, (+-)-
(+-)-2-(6-acetyl-m-toluidino)-2-(2,6-dichlorophenyl)acetamide
benzeneacetamide, alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-
CHEMBL37624 ,
2-(2-acetyl-5-methylanilino)-2-(2,6-dichlorophenyl)acetamide
unii-3s1r1lz09h
loviride [usan:inn:ban]
3s1r1lz09h ,
SCHEMBL247781
benzeneacetamide, .alpha.-((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-, (+/-)-
loviride [who-dd]
loviride [usan]
loviride [mart.]
(+/-)-2-(6-acetyl-m-toluidino)-2-(2,6-dichlorophenyl)acetamide
loviride [inn]
141030-40-2
2-((2-acetyl-5-methylphenyl)amino)-2-(2,6-dichlorophenyl)acetamide
Q6692646
HY-15355
CS-0005982
MS-25423
STARBLD0009613
DTXSID60869958
AKOS040741969

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1IC50 (µMol)8.25000.00010.22487.3200AID198387
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.01300.00040.61539.7000AID1421334
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID105866Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID105886Concentration required to inhibit the viral (HIV-2 ROD) cytopathic effect by 50% in MT-4 cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID105883Concentration required to inhibit the viral (HIV-1 IIIB strain) cytopathic effect by 50% in MT-4 cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID1421334Inhibition of HIV1 reverse transcriptase2018European journal of medicinal chemistry, Oct-05, Volume: 158Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID157403Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in peripheral blood lymphocytes (PBL).1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID198387Inhibitory effect on HIV-1 RT activity using template primer,poly (rA)-oligo (dT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID246299Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID246301Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID235702Selectivity index is the ratio of CC50 and EC50 in peripheral blood lymphocytes (PBL).1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID701104Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
AID105859Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID105884Concentration required to inhibit the viral (HIV-1 NL4.3 strain) cytopathic effect by 50% in MT-4 cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID105862Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID105860Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID246283Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID105864Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID105863Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID450503Antiviral activity against Human immunodeficiency virus 1 infected in human MT4 cells2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
The search for potent, small molecule NNRTIs: A review.
AID450504Selectivity index, ratio of human MT4 cytotoxicity to inhibition of HIV1 cytopathicity2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
The search for potent, small molecule NNRTIs: A review.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID235701Selectivity index is the ratio of CC50 and EC50 in MT-4 cells.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID105889Concentration that reduced the MT-4 cell viability by 50%.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID105861Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID246300Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID157393Cytotoxic concentration based on the reduction of viability of mock-infected peripheral blood lymphocytes (PBL)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID105887Concentration required to inhibit the viral (SIV mac251) cytopathic effect by 50% in MT-4 cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID105858Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID105127Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID246298Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID105885Concentration required to inhibit the viral (HIV-1 NNRTI resistant strain) cytopathic effect by 50% in MT-4 cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.
AID104785Cytotoxic concentration based on the reduction of viability of mock-infected cells1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (57.58)18.2507
2000's9 (27.27)29.6817
2010's5 (15.15)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.18 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (35.29%)5.53%
Reviews4 (11.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (52.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]